医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

A New Era Comes When Diabetes Can Be Treated Basically Using Cells of Pancreas

2014年12月09日 PM09:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

STC Stem Cell Treatment & Research Institute (www.stcstri.com) of STC Life Co., Ltd. (Chairman: Kye Ho Lee) succeeded in differentiating new pluripotent stem cells without side effect into beta-cells that control insulin in pancreas, after conducting research projects for several years. These new pluripotent stem cells can be differentiated into any tissues or organs without adverse effects.

Scientists at STC Stem Cell Treatment & Research Institute firstly created new pluripotent stem cells with no adverse effects and induced them to differentiate into beta-cells, and they identified their change into beta-cells 7 days thereafter. Then they identified the generation of intact beta-cells by tracing insulin genes that typically appear in beta-cells.

Along with success in differentiation of beta-cells, they also succeeded in differentiating into multiple cells in a short span of time. The research team led by Dr. Lee Sang-Yeon said that they generated beta-cells in these processes for the first time in the world.

The research outcome is expected to be immediately applied to treating diabetes as it shows no adverse effects with outstanding safety.

“With development of technology that can successfully differentiate STC pluripotent stem cells without side effects into beta-cells of pancreas, physicians now can treat basic cause of diseases rather than simply mitigating symptoms,” said Kye Ho Lee, Chairman of STC Life. “As we developed natural substances-based pluripotent stem cells (We refer to as STC EPN : Elicited pluripotent stem cell from natural compound) and technology of differentiating diverse cells using such stem cells, after successfully differentiating beta-cells for nerves, cartilages, liver, bone, fat and pancreas, we will be able to lead the world stem cell market. We will grow as the world’s top life science company by developing cell therapies with leading technologies.”

Established in 1989, STC Life is a life science company that concentrates on R&D of stem cells resources, genes related to controlling active oxygen in body (p62), life sciences, and energy water for agriculture.

STC Life developed Pluripotent stem cell without side effects, the first of its kind in the world, and it obtained a total of 58 patents in Korea and other countries, including 17 patents related with STC Pluripotent stem cells. It is also a therapy-oriented life science company that is treating incurable diseases and down-aging using mesenchymal stem cells at 97.7 B&H Clinic.

With the mission of realizing vision and dream of bringing disease-free healthy life to people and extending lifespan while creating the world with no poverty, STC Life will continuously develop new technologies to shape for the better future.

CONTACT

STC Life Co., Ltd.
Minsun Oh, +82 2 3438 0653
Director
msoh@stc365.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持